Our Technologies_JINWEI | Eliciting Natural Immune Responses

Our Technologies

Viral vectors play a crucial role in gene therapy, offering numerous advantages. The field of gene and cell therapy is experiencing a resurgence, driven by the introduction of next-generation vectors such as adenovirus, adeno-associated virus (AAV), and lentivirus. These advancements are revolutionizing therapeutic approaches and expanding the potential for effective treatments.

LENTIVIRAL VECTOR WITH DNA FLAP

Lentiviral Vector

Lentiviral vectors offer significant advantages in gene therapy, primarily due to their low immunogenicity and high efficiency in transducing both dividing and non-dividing cells. These vectors are non-replicative and non-pathogenic, with all virulence genes removed. Importantly, they provide long-term, stable expression of the transgene, making them suitable for a wide range of therapeutic applications.
Our innovative lentiviral vectors are designed to enable dendritic cells to train the immune system to target and destroy infected cellsor cancer cells.
By efficiently transducing dendritic cells, our vectors elicit a robust cellular immune response. Antigens are continuously presented through the endogenous pathway, leading to the physiological activation and maturation of key immune effectors. This process enhances the cytotoxic activity of T-cells, resulting in unprecedented therapeutic efficacy.

DNA FLAP - Mitosis-independent Replication of Lentiviruses

Research on viral vectors led to the discovery of the DNA FLAP, a unique 99-nucleotide sequence essential for the pre-integration complex of the virus to cross the nuclear membrane in non-dividing cells. This DNA FLAP enables lentiviruses to replicate independently of mitosis.

A lentiviral vector carries antigen genes from a pathogen or tumor cell.
The lentiviral vector transcripts and releases the mRNA that encodes the antigen into the dendritic cell.
Dendritic cells presents the antigens to T cells.
T cells recognize the antigens and kill the antigen-bearing cells (pathogens, infected or tumor cells).

ADVANTAGES AND APPLICATIONS OF OUR LENTIVIRAL VECTORS

Advantages

* Our vectors exhibit a strong proclivity for dendritic cells, the key cells for generating an effective T cell immune response.
* Equipped with DNA flap technology, our vectors can cross the nuclear membrane and deliver genes into the cell nucleus, allowing them to transduce non-dividing cells, such as dendritic cells.
* We offer both integrative and non-integrative vector options, providing flexibility for various therapeutic needs.
* Our vectors promote sustained antigen exposure through endogenous antigen presentation by dendritic cells, driving a robust T cell and antibody-mediated immune response.
* Our vectors stimulate a natural and potent immune response.
* Our vectors induce a strong, long-lasting memory response, along with regulatory control mechanisms that restore normal conditions once the pathogen or cancer cells are eliminated.
* Our vectors elicit a powerful T cell response, which is more effective than antibodies in targeting intracellular pathogens.

Applications

Infectious diseases immunotherapy
As key participant in projects led by the Ministry of Science & Technology and China National Health Commission, we are deeply committed to the challenging work of infectious disease prevention and control.
Currently, one of our most notable efforts is focused on the development of biopharmaceutical therapies for hepatitis B. This project has yielded a series of promising experimental results, demonstrating significant potential in addressing this widespread global health challenge.

Neoantigen cancer immunotherapy

We develop leading-edge therapies for various cancers by combining next-generation In-Silico Neoantigen identification methods with built-in lentiviral vector-based platform.

The current oncological indications are liver and prostate cancer therapies which are personalized treatment through targeting specific genetic aberrations harbored by each patient's tumor.

CRYPTIC PEPTIDES MODULATE TUMOR MICROENVIRONMENT

Our Cryptic Peptides

Jinwei’s Cryptic Peptide Technology Platform designs neoantigens tailored to individuals with different HLA immune subtypes, utilizing cryptic peptide modifications to trigger specific immune responses against autologous tumor cells. This platform has broad applications across various cancers, including lung cancer, digestive tract tumors, prostate cancer, breast cancer, kidney cancer, liver cancer, and more. It can be used as a standalone treatment or in combination with PD-1 therapies, offering significant advantages in both efficacy and safety.

From "Cold Tumors" into "Hot Tumors"

This neoantigen-based cryptopeptide product serves as a broad-spectrum solution for cancers expressing hTERT, which is highly and specifically expressed in over 80% of patients with advanced solid tumors. As a result, a majority of cancer patients, particularly those with "cold" or non-immunogenic tumors, can benefit from this innovative approach. These tumors typically evade immune detection through immune escape mechanisms, but Jinwei’s cryptic peptide product effectively modulates the tumor microenvironment, activates CD8+ T cells, and converts "cold tumors" into more immunogenic "hot tumors," significantly improving therapeutic outcomes.

Potential for Joint Application

Leveraging big data modeling algorithms and experimental insights, Jinwei’s Cryptic Peptide Technology Platform continuously refines cryptopeptide sequences to ensure efficient presentation and robust immune activation, breaking through immune tolerance and offering new treatment options for cancer patients. Its synergy with existing therapies, such as PD-1 inhibitors, further broadens the therapeutic landscape.
The Jinwei Cryptic Peptide Technology Platform can be combined with the lentiviral vector platform to create personalized antigen vector solutions for patients receiving tumor neoantigen therapy.